Table 6.

Univariate and multivariate Cox regression predicting all-cause mortality

	Univariate			Multivariate
	HR	95% CI	p-value	HR	95% CI	p-value
Preoperative
Age at surgery	1.05	1.02–1.08	<0.01	1.04	1.00–1.08	0.013
Sex (reference: female)	0.92	0.49–1.76	0.81	–	–	–
Intravesical therapy (Yes-No)	0.94	0.47–1.87	0.87	–	–	–
ECOG  1  2  3	1.9 1.38 4.8	0.98–3.70 0.57–3.33 9.4–17.5	<0.01 0.06 0.47 <0.01	1.3 0.78 3.0	0.62–2.76 0.30–2.04 6.6–12.0	<0.01 0.448 0.62 <0.01
NLR1 (continuous)	1.09	0.94–1.27	0.24	–	–	–
NLR1 ≥2.7 vs NLR1 <2.7	1.79	1.015–3.14	0.044	1.65	0.93–2.94	0.08
Postoperative
Adjuvant chemotherapy	1.15	0.35–3.75	0.81	–	–	–
pT3-4 vs pT ≤T2	3.67	2.08–6.47	<0.01	3.9	1.9–7.91	<0.01
Lymph node invasion (pN+ vs pN-)	2.39	1.24–4.63	<0.01	1.38	0.67–2.38	0.38
NLR2 (continuous)	0.98	0.94–1.02	0.37	–	–	–
NLR2 ≥2.7 vs NLR2 <2.7	0.56	0.17–1.8	0.33	–	–	–
NLR3 (continuous)	1.09	1.09–1.17	<0.01	1.11	1.02–1.21	0.01
NLR3 ≥2.7 vs NLR<2.7	1.01	0.53–1.91	0.96	–	–	–
NLR∆1 (continuous)	0.97	0.93–1.01	0.20	Not significant*
NLR∆2 (continuous)	1.05	1.05–1.09	0.028	Not significant*
NLR4 (continuous)	1.05	1.01–1.09	<0.01	Not significant*
NLR4 ≥2.7 vs NLR4 <2.7	1.99	1.18–3.34	<0.01	Not significant*

^*Separate models with pT stage, lymph node invasion, and separately NLR∆1, NLR∆2, NLR3, or NLR4.

HR – hazard ratio; CI – confidence interval; NLR – neutrophil-to-lymphocyte ratio; ECOG – Eastern Cooperative Oncology Group